Amylyx Pharmaceuticals (AMLX) Change in Acquisitions & Divestments (2022 - 2026)

Amylyx Pharmaceuticals' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $60.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments changed 0.0% year-over-year to $60.0 million; the TTM figure through Mar 2026 stood at $246.0 million (down 25.45% YoY), while the FY2025 annual figure was $246.0 million, down 28.49% from the prior year.
• Change in Acquisitions & Divestments was $60.0 million for Q1 2026 at Amylyx Pharmaceuticals, roughly flat from $60.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $147.9 million in Q4 2023 to a low of $24.9 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $72.0 million across 5 years, with a median of $64.0 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments jumped 335.06% in 2023, then slumped 56.06% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $34.0 million in 2022, then surged by 335.06% to $147.9 million in 2023, then plunged by 56.06% to $65.0 million in 2024, then dropped by 7.69% to $60.0 million in 2025, then changed by 0.0% to $60.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $60.0 million (Q1 2026), $60.0 million (Q4 2025), and $64.0 million (Q3 2025), per Business Quant data.